Sign inCreate account

Report workspace tools

NCT00318370COMPLETEDanonymous

A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse

Sponsor

Source record

Morphotek

Phase

Source record

PHASE2

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Farletuzumab, Chemo Plus Far

Indication / condition

AI-normalized

Ovarian Cancer

Intervention

Source record

Farletuzumab, Chemo Plus Far

Source & freshness

Source record

NCT ID

NCT00318370

Original source

ClinicalTrials.gov

Source last updated

Sep 09, 2015

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00318370

Title

A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse

Sponsor

Morphotek

Status

COMPLETED

Phase

PHASE2

Condition raw

Ovarian Cancer

Condition normalized

Ovarian Cancer

Modality raw

ovarian cancer

Modality normalized

monoclonal antibody

Target raw

Farletuzumab, Chemo Plus Far

Target normalized

Farletuzumab, Chemo Plus Far

Interventions

Farletuzumab, Chemo Plus Far

Public preview

Source record

A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse is a PHASE2 clinical asset sponsored by Morphotek in Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms. SEO and diligence focus: Farletuzumab, Chemo Plus Far, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00318370

Status

COMPLETED

Phase

PHASE2

Sponsor

Morphotek

Executive brief

Investment-Ready Snapshot

A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse is a PHASE2 clinical asset sponsored by Morphotek in Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms. SEO and diligence focus: Farletuzumab, Chemo Plus Far, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedSep 09, 2015
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00318370

Indication

Ovarian Cancer

Modality

monoclonal antibody

Target

Farletuzumab, Chemo Plus Far

Intervention

Farletuzumab, Chemo Plus Far

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.